TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.
about
Radiotherapy combination opportunities leveraging immunity for the next oncology practiceThe dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy.Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice.Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.Association detection between genetic variants in the microRNA binding sites of toll-like receptors signaling pathway genes and bladder cancer susceptibility.Profiling global kinome signatures of the radioresistant MCF-7/C6 breast cancer cells using MRM-based targeted proteomicsHypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.Radiation takes its TollTLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages.Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress.Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.A Multifaceted Role for Myd88-Dependent Signaling in Progression of Murine Mammary Carcinoma.Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapyDifferential effects of peptidoglycan on colorectal tumors and intestinal tissue post-pelvic radiotherapyRadiation and inflammation.Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.Emerging cytokine networks in colorectal cancer.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.Mechanisms regulating immune surveillance of cellular stress in cancer.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.Neutrophils, a candidate biomarker and target for radiation therapy?Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients.
P2860
Q26738443-22EE457C-FC50-4822-A3A8-E778CF324DF5Q34373036-366892EA-ED2F-4931-9E28-9D080ADC3949Q34616600-4117CCD2-A9DB-4942-A3BD-AE7EC0E4D76BQ34733049-EFCA7971-BFF2-499B-A914-D0A25ABD6796Q34733159-1AC15817-DECF-4BE5-92C3-6EA6ED229FDDQ34855520-14937454-AB2B-46EB-A9AF-0B6647AC499AQ35762937-02F2550C-69B1-4E31-BDF0-20240FA8A141Q35958114-D09BDF37-EDA6-4DEA-A592-FDE1FD8F97FBQ36083353-10515A82-42E4-47A5-A729-AC55454C348BQ36232040-FA170FBB-8F00-483B-91C0-4F1A35D2E185Q36319886-063A0F93-D831-4643-8187-2D766224F7B5Q36693228-1ADD8A58-515C-45EE-AF51-2D412B84E528Q36710940-EA33B51E-4C09-46FF-A533-B35947247039Q36755491-5C98C899-3B4A-4850-90E2-02B7DF714355Q37375375-E3400BB4-4A72-4D20-83B8-C8D620ADB8A6Q37614639-3A7C893D-8306-40D2-A03E-1241B73EBEDAQ37689006-70CFAA66-6462-4B82-9F36-C0FB0F4C4F67Q38284081-F030301B-2838-4947-BE5E-B5D954FEBD40Q38287775-EEC7A7A7-2161-4458-A69A-0CFE446BDB16Q38584430-16DEE236-86D6-4A20-90C1-D578145323A1Q38953721-C6790478-B78E-493E-A8B6-1CA88CA3667FQ39458697-C50EFC5E-5FF4-477B-A916-25B34183B6A3Q46189367-43464084-7EDA-43BC-B038-754B0640D005Q47575245-E0DB78D2-B45F-4CE9-ADAC-A3588DEEA25DQ47605309-85A0CBF5-69E5-40E4-ABD8-69CFDD74DCD4Q50056654-212B5E09-A4F4-413C-A375-DED5F7A669A4Q51802063-D737B082-25A6-459C-9C7F-6317FBEE645BQ55093340-1E5D388A-B797-4E8C-B70D-D9E6EE6B87AF
P2860
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@en
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@nl
type
label
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@en
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@nl
prefLabel
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@en
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@nl
P2093
P2860
P50
P1433
P1476
TLR9 signaling in the tumor mi ...... recurrence after radiotherapy.
@en
P2093
Andrew Raubitschek
Claudia M Kowolik
Dewan M S Hossain
Haiqing Li
Marcin Kortylewski
Peiguo Chu
Piotr Swiderski
Qifang Zhang
Sergey Nechaev
P2860
P304
P356
10.1158/0008-5472.CAN-13-1314
P407
P577
2013-10-23T00:00:00Z